The Cancer Institute collaborates with Benaroya Research Institute and the Digestive Disease Institute to offer liver and biliary duct cancer studies.

• A Phase 1b, Randomized, Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) in Combination With Cisplatin Plus Gemcitabine and PEGPH20 in Combination With Atezolizumab and Cisplatin Plus Gemcitabine Compared With Cisplatin Plus Gemcitabine in Subjects with Previously Untreated, Unresectable, Locally Advanced, or Metastatic Intrahepatic and Extrahepatic Cholangiocarcinoma and Gallbladder Adenocarcinoma
   
• Pexa-Vec (Vaccinia GM-CSF/Thymidine Kinase Deactived Virus) Followed by Sorafenib Versus Sorafenib in Patients with Advanced Hepatocellular Carcinoma (HCC) Without Prior Systemic Therapy
   
• TAS-120 IN PATIENTS WITH ADVANCED SOLID TUMORS WITH OR WITHOUT FGF/FGFR-RELATED ABNORMALITIES FOLLOWED BY A PHASE 2 STUDY IN PATIENTS WITH ADVANCED SOLID TUMORS WITH FGF/FGFR-RELATED
  ABNORMALITIES
  
  

• A Single-arm Feasibility Study of Gemcitabine, Cisplatin, and Nab-Paclitaxel as Neoadjuvant Therapy for Resectable Oncologically High-Risk Intrahepatic Cholangiocarcinoma
  
  

• A Phase 3, Open-Label, Randomized, Active-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Gemcitabine Plus Cisplatin Chemotherapy in First-Line Treatment of Participants With Unresectable or Metastatic Cholangiocarcinoma With FGFR2 Rearrangement (FIGHT-302)

  
   

If you would like to talk with a clinical research coordinator about clinical research trials related to liver and biliary duct cancer, call the Cancer Clinical Research Unit Research hotline at (206) 287-6270.